EDX Medical Group, a UK-based medical diagnostics company, has entered into a distribution agreement with Caris Life Sciences, a US-based AI and precision medicine firm. This partnership will see the two companies work together to distribute Caris’ advanced molecular profiling services in the UK and Nordic regions. The collaboration is set to last for a minimum of three years on an exclusive basis.
EDX Medical specialises in digital diagnostics that support personalised treatments for a range of serious conditions, including cancer and heart disease. Through this partnership, EDX Medical will immediately offer Caris’ molecular profiling services, including solid tumour and liquid biopsy testing, as well as AI-driven solutions in the UK, Sweden, Denmark, Norway, and Finland, with potential plans to expand into additional territories.
Professor Sir Chris Evans, the founder of EDX Medical, expressed that this agreement marks a significant step forward in the company’s mission to provide cutting-edge diagnostic tools that can positively impact patient outcomes. He emphasised the importance of using comprehensive molecular profiling for cancer patients to ensure the most effective treatments are identified swiftly.
Mike Hudson, CEO of EDX Medical, highlighted the shared vision between EDX and Caris, particularly their commitment to providing doctors with access to the best biological data from patient samples. Caris’ molecular profiling uses AI to analyse DNA, RNA, and proteins, helping physicians make more precise cancer treatment decisions.
Caris has developed one of the world’s largest platforms for cancer analysis, featuring Whole Exome and Whole Transcriptome Sequencing of over 23,000 genes. By analysing biomarkers in tumours, the company supports healthcare providers in offering personalised care.
David Spetzler, President of Caris Life Sciences, expressed enthusiasm for the partnership, noting that it aligns with the company’s mission to help clinicians worldwide make informed treatment decisions for their patients, ultimately improving patient outcomes.
This partnership brings together the expertise of two pioneering companies, both committed to advancing personalised healthcare and ensuring patients receive the best possible treatment based on their unique molecular profile.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
